


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+3.96%
-11.25%
-1.22%
+13.45%
CRMD
CorMedix
$10.64
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Expands stock buyback program

Outperform the market
CRMD Price Performance
$11.16 (-4.66%)
$13.03 (-18.34%)
$11.36 (-6.34%)
$8.31 (+28.04%)
CRMD has Fair risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

CRMD overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Earnings increase YoY

Above analyst estimates

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
CRMD Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
CRMD Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is CRMD current stock price?
What are CRMD stock strengths?
What is CRMD Risk Level?
What is CRMD market cap and volume?
What is CRMD current Stock IQ?
Should I buy CRMD stock right now?
Is CRMD a Strong Buy right now?
What does a 'Strong Buy' rating mean for CRMD?
What does a 'Strong Sell' rating mean for CRMD?
What factors influence CRMD's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+3.96%
-11.25%
-1.22%
+13.45%
CRMD
CorMedix
Current Price
$10.64
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Expands stock buyback program

Outperform the market

CRMD Price Performance
$11.16 (-4.66%)
$13.03 (-18.34%)
$11.36 (-6.34%)
$8.31 (+28.04%)
CRMD Analysts Opinion
CRMD Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Earnings increase YoY

Above analyst estimates

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
CRMD Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
CRMD Street Sentiment is extremely bullish and have positive views on the near-term outlook
CRMD has Fair risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
CRMD Stock IQ
CRMD Latest Analysis
Cormedix Director Trades $342K In Company Stock. CRMD) reported an insider sell on November 19 according to a new SEC filing. United States Securities and Exchange Commission on Wednesday unveiled the sale of 30000 shares of Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company'.s focus is on the commercialization of its product DefenCath in the United States (United States) and oth
Wed Nov 19, 2025
Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025. CorMedix Inc. (NASDAQ:CRMD) is one of the best breakout stocks to invest in. On November 13 H.C. Wainwrights Brandon Folkes reaffirmed a Buy on CorMedix Inc. (NASDAQ:CRMD) citing strong DefenCath-driven revenue Melinta acquisition synergies and multiple growth catalysts including Rezzayo and TPN Phase 3 data in 2026. Despite TDAPA pricing risks robust financials and pipeline [….]
Tue Nov 18, 2025
CorMedix: Raised Guidance NOL Confidence And Rezzayo Optionality Justify A Hold Rating.
Fri Nov 14, 2025
HC Wainwright & Co. Maintains CorMedix (CRMD) Buy Recommendation. Fintel reports that on November 13 2025 HC Wainwright &. Co. maintained coverage of CorMedix (NasdaqGM:CRMD) with a Buy recommendation. Analyst Price Forecast Suggests 76.78% Upside
Fri Nov 14, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CRMD Stock trends
CRMD Stock performance
CRMD Stock analysis
CRMD investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.